Josh Raskin

Drew detailed: Medicaid stable HBR year over year, marketplace recovering from -1% to approximately 4% pretax, PDP targeting 2% pretax (down from 3%+ in 2025), MA still slight loss but no PDR needed in 2026 indicating margin progression. Sarah noted premature to set long-term segment targets while policy still shaking out.

Sarah detailed 4 components baked into 2026 rates: adjusted 2025 baseline morbidity, healthy trend provision, eAPTC expiry impact, and composite view of program integrity risk pool shifts. September Wakely data consistent with extrapolation.

Drew confirmed net $300M subsidiary capital infusion needed in 2H, noting $4B undrawn credit facility with 39% debt-to-cap vs 60% covenant provides ample runway.

Drew confirmed all embedded earnings power drivers intact: Medicaid margin recovery, MA breakeven path, PDP margin expansion from 1% to 3%+, plus $6B more revenue.

Sarah explained the $130M is isolated to a consistent flu/ILI definition tracked for eight years, consistent with CDC's most acute flu season in fifteen years.

Sarah explained effectuation rates in line with norms, FTR impact more muted than expected but may have a longer tail into Q2.

Gail outlined three reasons for confidence: key earnings levers already in motion from 2025-2026, 2026 outlook intentionally prudent creating operating leverage capture opportunity, and path built on multiple independent levers not single assumption. Emphasized 2025 was about strengthening the foundation, 2026 about execution.

Mark deferred specific decomposition to January but noted what changed since July: more 2025 experience, updated state inputs including large states experiencing budget pressure. On coding, confirmed focus on accuracy and compliance with meaningful steps around data capture, clinical documentation, and vendor oversight.

Mark cited CMS marketplace integrity rule provisions as supportive. 2026 rate filings to capture current acuity plus expected further risk pool deterioration. Market likely smaller and higher acuity in 2026.

Felicia emphasized lifetime member value in bid strategy. Pete detailed targeted Carelon services: Mosaic primary care, post-acute, CareBridge home health, palliative care, and SpecialtyRx.

Mark confirmed above-historical commercial trends are fully priced for in a rational, hardened market. Gail explained MA growth trajectory aligns with 2024 cadence pattern.

Sam outlined three AI domains: administrative (revenue cycle, HR, supply chain), operational (throughput, scheduling, staffing, OR management), clinical ('holy grail', physician decision support from proprietary data, nursing safety tools). Accelerating EHR transition to standardize datasets.

Mike attributed strong cash flow to EBITDA growth, Parallon revenue cycle strength, robust working capital management, and $1.3B tax deferrals. Long-term cash flow management capabilities viewed as sustainable.

Mike noted outpatient surgery cases down 0.6% (improving trend) with 7.5-8% revenue growth. Total outpatient revenue up almost 8%. Inpatient surgeries flat, driven by Medicaid payer mix.

Sam outlined three AI categories: administrative (payroll, supply chain, HR), operational (staffing, scheduling, case management), and clinical (obstetrics tools with early success). Noted clinical is early stage.

Mike detailed 124 ASCs with revenue up 5-6% despite case volumes down 1%. Sam noted roughly 14 outpatient facilities per hospital on average, with CON states limiting expansion.

Celeste emphasized scale advantage from growth: significant OCR improvement from operating leverage even with Stars headwind. Cost cutting on track with Investor Day. Still has upside from group MA recontracting (several hundred bps to go), Medicaid J-curve, and CenterWell PCO clinic maturation. James reiterated commitment to adapting to wherever final rate notice lands.

David described evolution toward enterprise lifetime value including CenterWell integration. George emphasized multiyear view. Celeste added balance between long-term value and near-term delivery.

Celeste confirmed incremental $100M on top of prior several hundred million. Focused on transformation, AI, Stars. James added they pulled forward some 2026 investments but hit operational absorption limits.

James described strong patient growth from new clinics and same-store. V28 mitigation spot on. J curves maturing with consistent tranche performance.

Celeste confirmed a few hundred million in incremental investments across Stars, clinical excellence, and membership strategies. Declined to break down specific buckets or confirm 2025 as EPS floor.

Noel said 2026 pricing assumptions holding firm with 50 basis point MA margin improvement on track. Membership losses slightly north of expectations but within internal planning range. 2027 advance notice disappointing and likely requires similar dynamics to 2026 with benefit reductions and footprint reassessment. Too early for 2027 point estimates.

Conway gave revenue breakdown: 65% VBC, 15% fee-for-service care delivery, 20% payer/employer services. Within VBC about two-thirds from UHC and rest from diverse payers. Expects 2025 margins just under 3% with VBC under 1%. Nelson reaffirmed 6-8% long-term margin target and 5% VBC commitment.

Hemsley called long-term growth rate discussion somewhat academic given restart phase but said framework remains intact. Expects pacing back to low double-digit ranges. Noel confirmed no change to UHC targeted margin ranges with IRA adjustment moving MA from 3-5% to 2-4% mechanically. Commercial 7-9% target unchanged with path to recovery in 2027.

Triggered extended four-person response from Noel, Desai, Cianfrocco, and Witty. Desai explained plan exits in multi-payer geographies like Texas and Washington drove unengaged patients to Optum Health. Cianfrocco gave VBC refresher citing engagement, wraparound services, and behavioral health integration. Witty framed issues as second-order effects of 9% industry-wide price cuts.

Rex attributed to strategic deemphasis of standalone urgent care and narrow offerings. Dr. Desai explained post-V28 reshaping including legacy contract restructuring with one-time impacts. Best-ever patient engagement at 85% of value-based patients.

Miller said UHS now has better data showing where their pricing lags competitors in specific markets. Uses competitive benchmarking data in negotiations to justify rate increases even when overall performance is strong.

Filton said revenue growth of 5-6% acute and 6-7% behavioral exceeds cost inflation of ~4%, creating continued margin expansion opportunity. Both businesses able to continue improving margins in environment of stable costs and demand.

Filton described a mix of internal investment (Hippocratic AI), external vendors (ER coding), and proprietary development. AI coding hasn't elevated coding levels but improved efficiency.

Filton reported West Henderson achieved positive EBITDA in its first full quarter, better than expected. Behavioral demand remains strong per both macro data and internal inquiries.